He Hears Anthropic CEO Predicts AI Could Cure Cancer and Alzheimer’s Within 10 Years. He’s Skeptical, and Medicare May Cover the Clinical Trial Without Paying for the ...

Résumé détaillé

A 71-year-old chemo patient doubts the promise of a cure within a decade, yet a trial slot for an AI-designed drug might be on the table. Before he signs, he needs to know what lands on his Medicare bill.

Anthropic CEO Dario Amodei spoke in an IPO roadshow video. He said cancer, Alzheimer's, heart disease and mental illness "will be relics of the past in, I think, less than a decade". Business Insider reported on November 11, 2026 that physicians and researchers doubted the timeline and questioned the claim.

Consider a hypothetical 71-year-old retiree on Original Medicare, midway through chemotherapy for colon cancer. He reads the forecast and doubts the 10-year promise. A narrower question still nags him. If his oncologist offered a slot in a trial of an AI-designed drug, what would Medicare pay, and what would show up on his bill? The answer hits hardest for beneficiaries on Original Medicare with no Medigap policy, while patients with Plan G or Medicare Advantage face different math, covered below.

Karl Lauterbach, Germany's former health minister, wrote on X: "Curing cancer, Alzheimer's and mental illnesses can definitely benefit from AI. But that is impossible in just 10 years." Biotech executive Rami Elghandour called the remarks "insane things to say in an IPO pitch".

Seniors should know there is an easy quiz you can take to get up to nearly 75% off weight loss medications and GLP-1s starting at $50/month with Medicare. Take the quiz now and see if the Medicare GLP-1 Bridge Program works for you. (sponsor)

AI can speed up the front end of drug development: screening molecules and choosing candidates faster, but the back end still moves at the speed of human biology. A candidate must clear safety testing, dosing and efficacy studies and large confirmatory trials before the FDA reviews it, and an AI-designed compound gets no shortcut to approval, no guaranteed pharmacy shelf and no automatic Medicare coverage.

Under Medicare's current national coverage policy, effective July 9, 2007, Medicare covers routine costs in qualifying clinical trials, along with reasonable and necessary care to diagnose and treat complications arising from trial participation.

The Centers…

The…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.